Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients
Bone Marrow Transplant. 2021 Mar;56(3):745-748 doi: 10.1038/s41409-020-01073-0.
Metadata
| MESH HEADINGS: | Antilymphocyte Serum; Azithromycin; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Recurrence; Transplant Recipients; Transplantation Conditioning; Unrelated Donors |
|---|
Study Details
| Transplant Type: | Matched Unrelated Donor |
|---|---|
| Treatment: | GvHD Prophylaxis |
| Condition: | Acute Complications ; Acute Complications/Pulmonary Complications |
| Language: | eng |
| Credits: | Bibliographic data from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine |